廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,010.66
    +17.52 (+0.59%)
     
  • 道指

    39,760.08
    +477.75 (+1.22%)
     
  • 標普 500

    5,248.49
    +44.91 (+0.86%)
     
  • 納指

    16,399.52
    +83.82 (+0.51%)
     
  • Vix指數

    12.97
    +0.19 (+1.49%)
     
  • 富時100

    7,950.52
    +18.54 (+0.23%)
     
  • 紐約期油

    81.84
    +0.49 (+0.60%)
     
  • 金價

    2,214.80
    +2.10 (+0.09%)
     
  • 美元

    7.8233
    +0.0003 (+0.00%)
     
  • 人民幣

    0.9233
    +0.0001 (+0.01%)
     
  • 日圓

    0.0514
    -0.0000 (-0.06%)
     
  • 歐元

    8.4418
    -0.0273 (-0.32%)
     
  • Bitcoin

    70,555.94
    +707.01 (+1.01%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment

Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of JNJ-2113 (formerly PN-235).

JNJ-2113 is a macrocyclic peptide that binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells.

Also Read: Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study

Although peptides typically have low oral bioavailability, the high potency of JNJ-2113 and its oral stability indicated the potential for systemic activity beyond the gastrointestinal tract in rat models of inflammation and colitis.

廣告

In a rat trinitrobenzene sulfonic acid (TNBS)-induced colitis model, efficacy was observed as measured by attenuation of weight loss and colon inflammation with oral doses of JNJ-2113 as low as 0.3 mg/kg/day.

In an IL-23-induced rat skin inflammation model, orally dosed JNJ-2113 achieved inhibition of inflammation, equivalent to an IL-23 antibody, and reduced IL-17 and IL-22 cytokines.

Oral treatment with JNJ-2113 provided selective systemic IL-23 pathway inhibition in preclinical models.

"We look forward to the presentation of the Phase 2b FRONTIER 1 study data in adults with moderate-to-severe plaque psoriasis later this year," said Dinesh Patel, President & CEO.

Price Action: PTGX shares are up 1.97% at $25.21 on the last check Friday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.